2026 Annual Meeting | Florbetapir F 18 Live Reader Training by Eli Lilly and Company Date Tuesday 04/21/26 Time 01:00 PM - 03:30 PM CDT Add To Calendar Location Marriott Marquis Chicago | Daniel Burnham Session Format This program will be presented in-person only On Demand This program is not expected to be available in the meeting's On Demand product. Event Type Industry Therapeutic Update Topic(s) Aging, Dementia, and Behavioral Neurology Learning Objectives Florbetapir F 18 is a radioactive diagnostic drug indicated for Positron Emission Tomography (PET) imaging of the brain to estimate amyloid beta neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline and for selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products. Florbetapir F 18 reader training aims to equip attendees with essential skills to accurately interpret florbetapir amyloid PET scans. CME Available No CME available Program Materials Program Evaluations Event Timeline 01:00 PM - 03:30 PM CDT Speaker Florbetapir F 18 Live Reader Training Faculty Disclosures